華領醫藥(02552.HK)藥物確認實現重要里程碑 有權收取8億人幣里程碑付款
華領醫藥(02552.HK)公布,於8月17日,附屬華領上海與拜耳確認實現有關開發華堂寧的某個重要里程碑以及相關里程碑付款的支付。根據商業合作協定的條款,華領上海有權向拜耳收取一筆里程碑付款,金額為8億元人民幣。訂約雙方將根據商業合作協定安排相應的付款流程。
集團指,有關其全資附屬公司華領上海與拜耳訂立商業合作協定,以將dorzagliatin在中國商業化並就此建立戰略合作夥伴關係,早前華堂寧已獲批作為未經藥物治療的2型糖尿病患者的單獨用藥治療、華堂寧獲得批准與二甲雙胍聯合使用以治療二甲雙胍耐受性2型糖尿病人,及實現商業合作協定項下的另一項商業化里程碑,而收到拜耳的里程碑付款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.